Compare SWBI & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | SGP |
|---|---|---|
| Founded | 1852 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Ordnance And Accessories | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.8M | 650.9M |
| IPO Year | 2000 | N/A |
| Metric | SWBI | SGP |
|---|---|---|
| Price | $15.63 | $18.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $14.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 953.4K | 64.9K |
| Earning Date | 06-17-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 36.67 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $523,845,000.00 | N/A |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $39.32 | ★ N/A |
| Revenue Growth | ★ 10.36 | N/A |
| 52 Week Low | $7.73 | $17.06 |
| 52 Week High | $17.56 | $30.56 |
| Indicator | SWBI | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 44.16 |
| Support Level | $13.83 | $17.33 |
| Resistance Level | N/A | $20.25 |
| Average True Range (ATR) | 0.85 | 1.14 |
| MACD | 0.17 | 0.29 |
| Stochastic Oscillator | 52.50 | 57.88 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.